Rheumatology Advance Access originally published online on November 4, 2008
Rheumatology 2009 48(1):90; doi:10.1093/rheumatology/ken403
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Comment on: Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies
1Department of Pathology and Neurogenetics Networks, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Correspondence to: T. Liewluck, Department of Pathology and Neurogenetics Networks, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Rd, Siriraj, Bangkok 10700, Thailand. E-mail: sitll@mahidol.ac.th
| The first 10% of the full text of this article appears below. |
SIR, I read with great interest the article by Suzuki et al. [1] on clinical utility of anti-signal recognition particle (anti-SRP) antibody in the differential diagnosis of myopathies. Suzuki et al. [1] demonstrated that anti-SRP antibody is
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Suzuki, N. Suzuki, and M. Kuwana Comment on: Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies: reply Rheumatology, January 1, 2009; 48(1): 90 - 91. [Full Text] [PDF] |
||||
